Please use this identifier to cite or link to this item:
Title: Carvedilol inhibits the mitochondrial permeability transition by an antioxidant mechanism
Authors: Oliveira, Paulo 
Esteves, Telma 
Rolo, Anabela 
Palmeira, Carlos 
Moreno, António 
Issue Date: 2004
Citation: Cardiovascular Toxicology. 4:1 (2004) 11-20
Abstract: Abstract It was previously shown that carvedilol, a ß-adrenergic receptor antagonist with antioxidant properties, was able to inhibit the mitochondrial permeability transition (MPT). In the present work, the hypothesis was that the negative impact of carvedilol on the MPT was specifically the result of its antioxidant effect. For the current investigation, we used three different MPT inducers. MPT-associated events were tested to study the protective effect of both carvedilol and cyclosporin-A, the known MPT inhibitor. Carvedilol inhibited mitochondrial swelling with calcium plus phosphate and with calcium plus t-butylhydroperoxide, but not with calcium plus carboxyatractyloside. Carvedilol inhibited the oxidation of thiol groups with calcium plus phosphate (p<0.01) and with calcium plus t-butylhydroperoxide (p<0.05), but not with calcium plus carboxyatractyloside—in opposition to the full protection afforded by cyclosporin-A when using calcium and carboxyatractyloside. Our results showed that carvedilol was effective only when the MPT was triggered by a primary oxidative process. This finding implies that the antioxidant properties of carvedilol are crucial for the observed effects and reinforces the advantageous use of carvedilol in cardiac pathologies associated with enhanced cellular oxidative stress.
DOI: 10.1385/CT:4:1:11
Rights: openAccess
Appears in Collections:FCTUC Ciências da Vida - Artigos em Revistas Internacionais

Files in This Item:
File Description SizeFormat
obra.pdf74.52 kBAdobe PDFView/Open
Show full item record


checked on May 29, 2020

Page view(s)

checked on Oct 21, 2021


checked on Oct 21, 2021

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.